XRAY Q1 Deep Dive: Revenue Flat as Dentsply Sirona Advances Restructuring and Product Initiatives

Dental products company Dentsply Sirona (NASDAQ:XRAY) reported Q1 CY2026 results beating Wall Street’s revenue expectations, but sales were flat year on year at $880 million. On the other hand, the company’s full-year revenue guidance of $3.55 billion at the midpoint came in 0.7% below analysts’ estimates. Its non-GAAP profit of $0.27 per share was in line with analysts’ consensus estimates.

Is now the time to buy XRAY? Find out in our full research report (it’s free for active Edge members).

StockStory’s Take

Dentsply Sirona’s first quarter results reflected a company in the midst of operational transformation, with revenue holding steady year over year but outperforming Wall Street’s expectations. Management attributed the quarter’s performance to both ongoing restructuring efforts and investments in commercial capabilities, noting that early momentum is visible in customer engagement and new distribution partnerships. CEO Daniel T. Scavilla described the business as “in transition,” emphasizing that most benefits from these initiatives are yet to be realized, and acknowledging the ongoing impact of external market pressures and segment-specific headwinds.

Looking forward, Dentsply Sirona’s guidance hinges on disciplined execution of its return-to-growth action plan, continued investment in research and development, and improved distribution reach. Management highlighted that most of the operational and commercial benefits are expected to materialize later in the year and into 2027. Scavilla emphasized the company’s focus on customer-centric innovation, especially in implants and digital solutions, stating, “The vast majority of what we are doing to return the U.S. to growth is applicable throughout the world.”

Key Insights from Management’s Remarks

Management pointed to restructuring, product launches, and distribution expansion as key drivers shaping the quarter’s performance and setting the stage for future improvements.

• Restructuring gains underway: Dentsply Sirona continued to implement its cost optimization and organizational simplification program, achieving an early reduction of approximately $20 million in operating expenses, with most savings reinvested in growth areas such as R&D and commercial capabilities.
• New product innovation: The company launched SmartView Detect, an AI-enabled diagnostic aid for dental imaging, and expanded its endodontics portfolio with the Reciproc Minima File System and X-Smart Go cordless endomotor. These introductions are positioned to improve clinical outcomes and workflow efficiency for dental practitioners.
• Distribution network expansion: Four new distributor agreements were signed in the U.S. during the quarter, increasing regional coverage and access to Dentsply Sirona’s connected technology solutions. Early traction was noted, with distribution partners like Benco achieving milestones ahead of schedule.
• Segment performance challenges: EDS and CTS segments faced volume declines, particularly in Europe, which management linked to dealer destocking and a tough year-ago comparison. The APAC region was highlighted as a source of growth due to strong leadership and focus on clinical education.
• Tariff and input cost headwinds: Gross margin contraction was driven by increased tariffs and input costs, with management expecting some relief in the coming quarters as inventory dynamics normalize and cost-saving measures take hold.

Drivers of Future Performance

Dentsply Sirona’s outlook is shaped by ongoing restructuring, targeted innovation, and efforts to revitalize core markets amid persistent cost and demand pressures.

• Timing of restructuring benefits: Management expects most cost savings and operational improvements from restructuring to materialize in the second half of the year and into 2027, with early indicators already visible in reduced expenses and increased commercial focus.
• Product and market expansion: Growth will be driven by continued investment in R&D, further launches of AI-enabled and digital dental products, and expansion of the U.S. and international distribution network. The company believes these actions will help it regain market share in key categories, particularly implants and CAD/CAM (computer-aided design and manufacturing) systems.
• External risks and margin pressures: Persistent industry headwinds, including tariff impacts and dealer destocking, remain a risk to near-term profitability. Management does not expect significant price increases to offset these pressures and is instead focused on cost management and portfolio differentiation.

Catalysts in Upcoming Quarters

Over the coming quarters, the StockStory team will focus on (1) the pace and impact of restructuring savings and how quickly they translate to margin improvement, (2) the adoption trajectory for new AI-enabled diagnostic products and broader digital portfolio uptake, and (3) the effectiveness of expanded distribution partnerships in driving U.S. and international market share gains. Progress in revitalizing core segments like implants and CAD/CAM will be additional key markers for the company’s turnaround.

Dentsply Sirona currently trades at $11.42, in line with $11.37 just before the earnings. Is the company at an inflection point that warrants a buy or sell? See for yourself in our full research report (it’s free).

Stocks That Trumped Tariffs

ONE MORE THING: Top 5 Growth Stocks. The biggest stock winners almost always had one thing in common before they ran. Revenue growing like crazy. Meta. CrowdStrike. Broadcom. Our AI flagged all three. They returned 315%, 314%, and 455%, respectively.

Find out which 5 stocks it's flagging for this month - FREE. Get Our Top 5 Growth Stocks for Free HERE.

Stocks that have made our list include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Kadant (+351% five-year return). Find your next big winner with StockStory today.